Findings

What do systematic reviews say?

23 questions · 23 findings · 4 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 34.8%GRADE not reported 7 · 30.4%Very low 3 · 13%Low 1 · 4.3%Moderate 4 · 17.4%High 0 · 0%

Betamethasone oral mini-pulse therapy vs Topical triamcinolone acetonide paste

Side effects · People with erosive oral lichen planus

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
Table 3 (Side-effects). Malhotra 2008: betamethasone oral mini-pulse - transient oedema over the face (7), oedema over hands and feet (4), epigastric discomfort (7), weakness/fatigue (5), loose stools (1), headache…
1 study · 22 participants
GRADE not reported

Betamethasone oral mini-pulse therapy vs Topical triamcinolone acetonide paste

Investigator‐ or physician‐rated global assessment of disease severity · People with erosive oral lichen planus

Betamethasone oral mini-pulse therapy led to higher physician Global Assessment (clinical severity, 0-12 score) compared with topical triamcinolone acetonide 0.1% paste; GRADE not reported.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
24 weeks
MD 1.78 [0.17, 3.39]
1 study · 22 participants
GRADE not reported

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral classical immunosuppressants… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral classical immunosuppressants (azathioprine, methotrexate,… (low certainty).

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
RR 1.67 [0.96, 2.88]
2 studies · 80 participants
Low

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Incidence of serious adverse events · adults with alopecia areata

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 154 participants
Very low

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

Incidence of serious adverse events · adults with alopecia areata

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 543 participants
Very low

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Intralesional classical… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
RR 13.84 [0.87, 219.76]
1 study · 231 participants
Very low

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Primary: investigator‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: investigator‐ rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
RR 1.88 [0.88, 3.99]
1 study · 34 participants
Moderate

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Primary: participant‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: participant‐rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
RR 1.25 [0.69, 2.27]
1 study · 34 participants
Moderate

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
RR 1.22 [0.8, 1.86]
1 study · 55 participants
Moderate

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Secondary: investigator‐rated reduction in severity ‐ DASIb · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Moderate

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Clearing or excellent improvement · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
GRADE not reported

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

At least 50% reduction in erythema · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Quality of life measure · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fluticasone propionate spray vs Betamethasone sodium phosphate mouthwash

Secondary outcome: Dermatology Quality of Life measure · People with erosive oral lichen planus

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No statistical testing of the Oral Health Quality of Life index (OHQoL16) was reported in Hegarty 2002 (fluticasone mean score 0.7 versus betamethasone mean score -0.8).
1 study · 22 participants
GRADE not reported